Dr Rebecca Lumsden, Head of Science Policy at the ABPI, comments on the Government funding for the next generation of medical advances which was published today.
Dr Rebecca Lumsden said: "The ABPI welcomes the announcement that the Medical Research Council and the Innovate UK are committing an additional £18 million to enable innovative life science projects through this round of the Biomedical Catalyst.
"This is a welcome boost to small and medium sized enterprises which will enable them to take forward discoveries with proof of concept, including addressing key health challenges such as antimicrobial resistance, to the next stage of development. I'm delighted to see Government recognition for our colleagues in life sciences research. Universities and SMEs play an important role in modern medical research, and the universities and SMEs granted funds today, along with those that will receive awards in future, are among our key allies and partners in developing the next generation of medicines. This investment further highlights the commitment by the government to boost the life sciences sector and emphasises the importance of this sector to the wider economy."
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press OfficeTelephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811Email: email@example.com